The New England journal of medicine, 2018-02, Vol.378 (7), p.615-624
2018
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
- Ist Teil von
- The New England journal of medicine, 2018-02, Vol.378 (7), p.615-624
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2018
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In a randomized trial, 1050 patients with cancer who had acute venous thromboembolism were assigned to receive either dalteparin or edoxaban for 6 to 12 months. Edoxaban was noninferior to dalteparin with respect to the outcome of recurrent venous thromboembolism or major bleeding.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1711948Titel-ID: cdi_proquest_journals_2003032747
- Format
- –
- Schlagworte
- Adult, Aged, Anticoagulants, Anticoagulants - adverse effects, Anticoagulants - therapeutic use, Bleeding, Body weight, Cancer, Cancer therapies, Dalteparin - adverse effects, Dalteparin - therapeutic use, Drug dosages, Embolisms, Follow-Up Studies, Health risk assessment, Hematology, Hemorrhage - chemically induced, Heparin, Heparin, Low-Molecular-Weight - adverse effects, Heparin, Low-Molecular-Weight - therapeutic use, Humans, Intention to Treat Analysis, Kaplan-Meier Estimate, Male, Medicine, Metastasis, Middle Aged, Neoplasms - complications, Pulmonary arteries, Pyridines - adverse effects, Pyridines - therapeutic use, Recurrence, Thiazoles - adverse effects, Thiazoles - therapeutic use, Thromboembolism, Thrombosis, Veins & arteries, Venous Thromboembolism - drug therapy, Venous Thromboembolism - etiology